 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Sep 18, 2018 |
| Title |
Global gene expression profile of dasatinib-resistant RCH-ACV cells |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Purpose: Several ALL subtypes have been described depending on their karyotype, cell type, immunophenotype and gene-expression profile. Recently, a novel ALL subtype has been described and is characterized by expression of the pre-B cell receptor (pre-BCR). Interestingly, half of the cases is associated with the chromosomal translocation t(1:19), coding for the chimeric fusion protein E2A-PBX1, which is present in about 5% of pediatric and adult ALL. Using preclinical models, we and other groups have shown very promising preclinical activity of dasatinib in pre-BCR+ ALL and early clinical evidence supports our observations. To study mechanism of acquired dasatinib resistance, we generated dasatinib-resistant pre-BCR+/E2A-PBX1+ cell lines through multiple passages in the presence of increasing drug concentrations. Whole transcriptome analysis of dasatinib-sensitive and resistant ALL cells were performed to detect systematically differentially expressed genes and enriched pathways involved in dasatinib resistance.
|
| |
|
| Overall design |
RNA was isolated at three different time points (replicates) from two independent generated dasatinib-resistant RCH-ACV sublines. Replicates from control dasatinib-sensitive RCH-ACV cell sublines were used as controls.
|
| |
|
| Contributor(s) |
Duque-Afonso J, Lin C, Han K, Morgens DW, Jeng EE, Weng Z, Jeong J, Wong SH, Zhu L, Wei MC, Chae H, Sakamoto KM, Bassik MC, Cleary ML |
| Citation(s) |
37686604 |
|
Duque-Afonso J, Lin CH, Han K, Morgens DW, Jeng EE, Weng Z, Jeong J, Wong SH, Zhu L, Wei MC, Chae H-D, Schrappe M, Cario G, Duyster J, Sakamoto KM, Bassik MC, Cleary ML. CBP modulates dasatinib sensitivity in pre-BCR+ acute lymphoblastic leukemia. Cancer Res. 2018 (in press).
|
| |
| Submission date |
Apr 03, 2017 |
| Last update date |
Sep 15, 2023 |
| Contact name |
Jesus Duque-Afonso |
| E-mail(s) |
jduque@stanford.edu
|
| Organization name |
Stanford University
|
| Department |
Pathology
|
| Lab |
Dr. Michael Cleary
|
| Street address |
265 Campus Drive
|
| City |
Stanford |
| State/province |
CA |
| ZIP/Postal code |
94305 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (12)
|
| GSM2562110 |
RCH-ACV dasatinib sensitive clone 1 [SCGPM_160503_A_C8F37_CGATGT] |
| GSM2562111 |
RCH-ACV dasatinib sensitive clone 1 [SCGPM_160503_A_C8F37_TGACCA] |
| GSM2562112 |
RCH-ACV dasatinib sensitive clone 1 [SCGPM_160503_A_C8F37_GCCAAT] |
| GSM2562113 |
RCH-ACV dasatinib resistant clone 1 [SCGPM_160503_A_C8F37_CAGATC] |
| GSM2562114 |
RCH-ACV dasatinib resistant clone 1 [SCGPM_160503_A_C8F37_CTTGTA] |
| GSM2562115 |
RCH-ACV dasatinib resistant clone 1 [SCGPM_160503_A_C8F37_CCGTCC] |
| GSM2562116 |
RCH-ACV dasatinib sensitive clone 2 [SCGPM_160503_B_C8F37_CGATGT] |
| GSM2562117 |
RCH-ACV dasatinib sensitive clone 2 [SCGPM_160503_B_C8F37_ACAGTG] |
| GSM2562118 |
RCH-ACV dasatinib sensitive clone 2 [SCGPM_160503_B_C8F37_GCCAAT] |
| GSM2562119 |
RCH-ACV dasatinib resistant clone 2 [SCGPM_160503_B_C8F37_CAGATC] |
| GSM2562120 |
RCH-ACV dasatinib resistant clone 2 [SCGPM_160503_B_C8F37_CTTGTA] |
| GSM2562121 |
RCH-ACV dasatinib resistant clone 2 [SCGPM_160503_B_C8F37_CCGTCC] |
|
| Relations |
| BioProject |
PRJNA381484 |
| SRA |
SRP102945 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE97352_RNAseq.clone1.result.in_dasatinib_resistant_for_GEO.txt.gz |
636.0 Kb |
(ftp)(http) |
TXT |
| GSE97352_RNAseq.clone2.result.in_dasatinib-resistant_for_GEO.txt.gz |
685.5 Kb |
(ftp)(http) |
TXT |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...